AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
ASTRAZENECA PHARMA | CADILA HEALTHCARE | ASTRAZENECA PHARMA/ CADILA HEALTHCARE |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 141.2 | 29.7 | 475.3% | View Chart |
P/BV | x | 39.6 | 4.8 | 828.4% | View Chart |
Dividend Yield | % | 0.0 | 0.7 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
CADILA HEALTHCARE Mar-20 |
ASTRAZENECA PHARMA/ CADILA HEALTHCARE |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 352 | 362.8% | |
Low | Rs | 883 | 207 | 427.4% | |
Sales per share (Unadj.) | Rs | 228.4 | 139.2 | 164.1% | |
Earnings per share (Unadj.) | Rs | 10.4 | 11.8 | 88.1% | |
Cash flow per share (Unadj.) | Rs | 16.3 | 18.6 | 87.6% | |
Dividends per share (Unadj.) | Rs | 0 | 3.50 | 0.0% | |
Dividend yield (eoy) | % | 0 | 1.3 | 0.0% | |
Book value per share (Unadj.) | Rs | 98.8 | 101.4 | 97.5% | |
Shares outstanding (eoy) | m | 25.00 | 1,023.74 | 2.4% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 2.0 | 235.7% | |
Avg P/E ratio | x | 104.2 | 23.7 | 438.9% | |
P/CF ratio (eoy) | x | 66.4 | 15.0 | 441.5% | |
Price / Book Value ratio | x | 10.9 | 2.8 | 396.7% | |
Dividend payout | % | 0 | 29.8 | 0.0% | |
Avg Mkt Cap | Rs m | 27,008 | 286,033 | 9.4% | |
No. of employees | `000 | 1.4 | 13.4 | 10.1% | |
Total wages/salary | Rs m | 1,535 | 24,145 | 6.4% | |
Avg. sales/employee | Rs Th | 4,210.9 | 10,632.7 | 39.6% | |
Avg. wages/employee | Rs Th | 1,132.2 | 1,801.2 | 62.9% | |
Avg. net profit/employee | Rs Th | 191.1 | 898.5 | 21.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 142,531 | 4.0% | |
Other income | Rs m | 123 | 1,139 | 10.8% | |
Total revenues | Rs m | 5,833 | 143,670 | 4.1% | |
Gross profit | Rs m | 463 | 24,198 | 1.9% | |
Depreciation | Rs m | 147 | 6,965 | 2.1% | |
Interest | Rs m | 0 | 3,418 | 0.0% | |
Profit before tax | Rs m | 438 | 14,954 | 2.9% | |
Minority Interest | Rs m | 0 | 288 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 179 | 3,198 | 5.6% | |
Profit after tax | Rs m | 259 | 12,044 | 2.2% | |
Gross profit margin | % | 8.1 | 17.0 | 47.8% | |
Effective tax rate | % | 40.8 | 21.4 | 191.0% | |
Net profit margin | % | 4.5 | 8.5 | 53.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 87,154 | 3.7% | |
Current liabilities | Rs m | 2,070 | 82,694 | 2.5% | |
Net working cap to sales | % | 20.0 | 3.1 | 637.9% | |
Current ratio | x | 1.6 | 1.1 | 147.1% | |
Inventory Days | Days | 72 | 71 | 101.3% | |
Debtors Days | Days | 35 | 94 | 37.2% | |
Net fixed assets | Rs m | 790 | 133,236 | 0.6% | |
Share capital | Rs m | 50 | 1,024 | 4.9% | |
"Free" reserves | Rs m | 2,419 | 102,733 | 2.4% | |
Net worth | Rs m | 2,469 | 103,757 | 2.4% | |
Long term debt | Rs m | 0 | 32,146 | 0.0% | |
Total assets | Rs m | 4,605 | 236,866 | 1.9% | |
Interest coverage | x | NM | 5.4 | - | |
Debt to equity ratio | x | 0 | 0.3 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.6 | 206.0% | |
Return on assets | % | 5.6 | 6.5 | 86.2% | |
Return on equity | % | 10.5 | 11.6 | 90.4% | |
Return on capital | % | 17.7 | 13.7 | 129.2% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 300 | 52,752 | 0.6% | |
Fx outflow | Rs m | 2,015 | 14,504 | 13.9% | |
Net fx | Rs m | -1,715 | 38,248 | -4.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 25,054 | 0.4% | |
From Investments | Rs m | -94 | -10,123 | 0.9% | |
From Financial Activity | Rs m | NA | -10,942 | 0.0% | |
Net Cashflow | Rs m | -6 | 3,989 | -0.1% |
Indian Promoters | % | 0.0 | 74.8 | - | |
Foreign collaborators | % | 75.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.3 | 8.3 | 3.6% | |
FIIs | % | 15.7 | 5.9 | 266.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 9.1 | 11.0 | 82.7% | |
Shareholders | 12,856 | 44,069 | 29.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: SHASUN PHARMA WYETH ABBOTT INDIA SUVEN LIFE SCIENCES DR. REDDYS LAB
Compare ASTRAZENECA PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 140 points, up 0.3% at 49,538 levels.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More